



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Datasheet for 000-001-L17

Beta Amyloid 3-40 Peptide**Overview**

| | |
|---------------------|---|
| Description: | Beta Amyloid 3-40 Peptide - 000-001-L17 |
| Item No.: | 000-001-L17 |
| Size: | 1 mg |

Product Details

| | |
|--------------------|---|
| Background: | Amyloid peptides, derived from amyloid precursor protein (APP), are thought to play a role in the development of the senile plaques associated with Alzheimer's disease. The amyloid hypothesis presupposes that flaws in the processing of APP result in abnormally high levels of the longer, "stickier" forms of beta amyloid, known as A β 42 and A β 43, leading to aggregation of amyloid in the neuronal cell death and ultimately neuronal death. Mutations in the structure of A β 40 and related peptides as well as in some of the enzymes involved in the processing of APP have been shown to alter the processing of APP. The sporadic (i.e., non-genetic) form of the disease, however, is far more common, caused by aging in concert with a number of both genetic and environmental risk factors. |
| Synonyms: | ABPP, APP1, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, Protease nexin-II, control peptide, blocking peptide |
| Type: | Peptide |

Target Details

| | |
|----------------------------|------------------------------------|
| Purity/Specificity: | Greater than 95% specific peptide. |
|----------------------------|------------------------------------|

Application Details

| | |
|--------------------------|---|
| Application Note: | Beta Amyloid 3-40 Control Peptide is suitable for use in ELISA, Western Blot, Dot blot, PCA, and other assays. Control peptide should be used at 1.0 μ g per 1.0 μ l of antiserum in per assay. Specific conditions for reactivity should be optimized by the end user. |
| Assay Dilutions: | All assays should be optimized by the user. Recommended dilutions (if any) may be listed below. |

Formulation

| | |
|-------------------------------|--|
| Physical State: | Lyophilized |
| Concentration: | 1.0 mg/mL by dry weight |
| Buffer: | None |
| Reconstitution Volume: | 1.0 mL |
| Reconstitution Buffer: | Restore with deionized water (or equivalent) |

Shipping & Handling

| | |
|----------------------------|---|
| Shipping Condition: | Ambient |
| Storage Condition: | Store vial at 2 - 8 ° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use. |
| Expiration: | Expiration date is one (1) year from date of receipt. |

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

